Merck and Siemens Strengthen Partnership to Drive AI and Data-Led Drug Development
Wednesday, September 24, 2025
Merck, a global science and technology company, has expanded its strategic partnership with Siemens through a new Memorandum of Understanding (MoU). The agreement aims to accelerate digital transformation in the life sciences sector by advancing integrated software, systems, and consumables that use automation, artificial intelligence, and data to connect drug discovery, development, and manufacturing.
The MoU is the first initiative to apply technology acquired by Siemens through its recent purchase of Dotmatics in July 2025. It will bring Merck’s software-as-a-service products into Siemens’ digital ecosystem, enabling a stronger link between laboratory research and production.
Initial pilot projects include integrating Merck’s AI tools and digital applications into Siemens’ Dotmatics Scientific Intelligence Platform, Luma. This will allow scientists to access digital tools, insights, and product ordering from a single platform, helping them to make quicker, data-led decisions.
Beyond pilot programmes, the two companies plan to work on new projects that include developing smarter data management systems, simplified interfaces, and digital marketplaces that provide easier access to complementary technologies and services.
The collaboration builds on previous agreements between Merck and Siemens in smart manufacturing. By deepening their partnership, both companies aim to set a new standard for digital transformation in life sciences, supporting faster scientific progress and improved access to advanced therapies.
Source: businesswire.com
